Search results
Metabolic Surgery Superior to GLP-1 RAs for Long-Term Outcomes in Patients with Diabetes and Obesity
Added:
8 months ago
Source:
Radcliffe CVRM
News
Added:
7 months ago
Source:
Radcliffe CVRM
A novel, selective amylin receptor agonist, eloralintide, has demonstrated significant, dose-dependent weight loss in adults with obesity or overweight, according to the results of a 48-week phase 2 trial (NCT06230523).¹ Amylin-based therapies are an emerging class of promising medications for weight management.²This multicentre, double-blind, randomised, placebo-controlled trial was conducted…
View more
Added:
6 months ago
Source:
Radcliffe Cardiology
A new post hoc analysis of the SUMMIT trial suggests the HFpEF-ABA score is a more effective and inclusive enrichment tool than natriuretic peptide (NP) levels for clinical trials in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).¹ The findings indicate the score, which is based on age, body mass index (BMI), and history of atrial fibrillation (AF), can…
View more
Added:
6 months ago
Source:
Radcliffe CVRM
A new pooled analysis suggests that measures of abdominal adiposity, such as waist-to-height ratio, are better predictors of clinical outcomes than body mass index (BMI) alone in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Obesity is highly prevalent in this patient population and is linked to an increased risk of mortality and disability.This…
View more
Added:
5 months ago
Source:
Radcliffe CVRM
A new study has defined a metabolome-informed body mass index (metBMI) that more accurately reflects adiposity and cardiometabolic risk than the traditional BMI calculation.² The findings, published in Nature Medicine, suggest this multi-omic approach could help identify high-risk individuals whose metabolic dysfunction is not captured by conventional measures.¹MethodologyResearchers developed…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
The primary drivers of heart failure (HF) have shifted significantly over the past 35 years, with metabolic conditions such as obesity and diabetes now playing a more prominent role than traditional risk factors like myocardial infarction (MI).¹˒² This finding comes from a large US-based study analysing national health trends.MethodologyResearchers conducted a retrospective analysis of data from…
View more
Added:
5 months ago
Source:
Radcliffe CVRM
A novel, once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist, orforglipron, has demonstrated superior weight loss compared to placebo in adults with obesity or overweight and type 2 diabetes, according to results from the ATTAIN-2 trial.¹Orforglipron is an oral, non-peptide, small-molecule GLP-1 receptor agonist, offering a potential alternative to injectable therapies for weight…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: David RamseyAmerican Diabetes Scientific Sessions, 21 June, 2024 – In a Phase III trial (SURMOUNT-OSA,NCT05412004)of patients with moderate-to-severe sleep apnea and obesity, tirzepatide demonstrated significant improvements in both sleep apnea scores as well as cardiometabolic risk factors including body weight, hsCRP and systolic blood pressure.SURMOUNT-OSA investigated tirzepatide’s…
View more
Added:
5 months ago
Source:
Radcliffe CVRM
A pragmatic, scalable approach to obesity implemented in primary care has the potential to curtail population weight gain, according to findings from the PATHWEIGH trial. The study found that a multi-component care process successfully mitigated the weight gain observed with usual care and increased the likelihood of patients receiving weight-related treatment.¹The PATHWEIGH intervention…
View more
Added:
5 months ago
Source:
Radcliffe CVRM
Following the primary analysis of the SELECT trial, which demonstrated that semaglutide reduces major adverse cardiovascular events, a new exploratory analysis suggests the treatment also significantly lowers the rate and duration of hospitalisations in patients with established cardiovascular disease (CVD) and overweight or obesity, but without diabetes.¹MethodologyThis prespecified exploratory…
View more